Following the company’s fourth quarter results, Ventum Capital Markets analysts Andrew Semple has maintained his “Buy” rating on Vext Science (Vext Science Stock Quote, Chart, News, Analysts, Financials CSE:VEXT).
On March 31, VEXT reported its Q4 and fiscal 2024 results. In the fourth quarter, the company posted Adjusted EBITDA of $3.24-million on revenue of $10.2-million, a topline that was up 19.4%, year-over-year.
“2024 was a pivotal year for Vext, as we successfully executed our strategy and delivered strong growth despite a challenging consumer environment,” CEO Eric Offenberger said. “The launch of Ohio’s adult-use market marked an inflection point, and we are already seeing the benefits from our investments in the state, with Q4 2024 revenue growing 13% sequentially to $10.2 million. Our Jackson and Columbus retail locations, combined, delivered ~40% sequential growth in Q4, demonstrating…
